Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful ...

Women in Healthcare Leadership podcast series. Now on its fourth series, “Hear from Her” has established itself globally as ...

Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form ...

In the emerging framework, a medicine’s value will increasingly depend on how effectively care is delivered around it’ ...

Global Pricing Innovations supports price decision-making through data-driven insights and bespoke analytical solutions. GPI tools and services maximize clients’ price and value understanding and ...

For decades, the rate of spontaneous preterm birth in the United States has hovered stubbornly around 10%. Despite advancements in other areas of medicine, prematurity remains the second leading cause ...

Zymeworks, a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of ...

Roche’s Enspryng (satralizumab), a thyroid eye disease (TED) treatment, has been accepted by the FDA and given priority ...

For pharma, its AI progress appears to be slowed by a methodical procession of AI adoption through a series of chicanes.

Oxford BioTherapeutics (OBT) has announced two clinical milestones from its long-running oncology collaboration with ...

Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective 6 July 2026. Sims is a seasoned oncology ...

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication ...